Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?

Prestige Consumer Healthcare (PBH) is focused on long-term growth through brand building, e-commerce expansion, and strategic acquisitions, with e-commerce now representing a high-teens percentage of total sales. Despite a 30.9% stock rally in the past year, the company faces challenges including a $1.01 billion long-term debt and potential foreign exchange headwinds that could impact fiscal 2026 revenue growth by approximately one percentage point; PBH anticipates organic revenue growth of approximately 1% to 2% for fiscal 2026.

Analysis

Prestige Consumer Healthcare (PBH) demonstrates a focused growth strategy centered on brand-building, e-commerce expansion, and strategic acquisitions. The company has achieved significant e-commerce momentum, with sales growing at a double-digit rate in fiscal 2025 and now constituting a high-teens percentage of total revenue, up from approximately 15% in the prior year, partly accelerated by anticipated tariff actions in Q4. Key brands like Hydralyte, Dramamine, Fleet, Monistat, and Summer’s Eve maintain strong market positions, supported by ongoing innovation such as new product flavors and formulations. Acquisitions, including TheraTears and Hydralyte, have diversified PBH's portfolio, providing multiple growth avenues. Financially, PBH's stock has rallied 30.9% in the past year, outperforming the industry and S&P 500's 9.1% growth, and it boasts an earnings yield of 5.6%, significantly above the industry's 0.6%. The company has also consistently surpassed earnings estimates, with an average surprise of 2.8% over the trailing four quarters. However, concerns exist regarding its financial leverage; PBH carries $1.01 billion in long-term debt against $98 million in cash and cash equivalents, resulting in a debt-to-capital ratio of 35.6% and a times interest earned ratio of 7, suggesting potential challenges in meeting interest obligations. Furthermore, with 15.6% of fiscal 2025 revenues derived internationally, currency fluctuations pose a risk to profitability. For fiscal 2026, PBH anticipates modest organic revenue growth of 1% to 2%, with an expected foreign exchange headwind of approximately one percentage point. The Zacks Consensus Estimate for fiscal 2026 EPS is $4.77, reflecting a slight increase, while revenue is projected at $1.15 billion, a 0.9% year-over-year increase.

Key Decisions for Investors

• Investors should weigh PBH's strong brand portfolio and e-commerce momentum against the modest fiscal 2026 organic revenue growth forecast of 1-2% and an anticipated one percentage point currency headwind.
• Carefully monitor PBH's debt servicing capacity, given its $1.01 billion long-term debt and a times interest earned ratio of 7, as this could impact financial flexibility and profitability, especially if earnings falter or interest rates rise.
• Given the stock's significant 30.9% rally over the past year and the identified financial leverage and currency risks, investors should assess if the current valuation adequately reflects both the company's growth drivers and its potential headwinds before making new investment decisions.